Medicinal Chemistry Research Program (Project-003)

药物化学研究计划（Project-003）

• 批准号: 9369068
• 负责人: DEBORAH W KNAPP
• 金额: $ 2.84万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9369068
• 关键词: Antineoplastic Agents; Award; Basic Science; Cancer Center Support Grant; Canis familiaris; Cells; Chemicals; Clinic; Collaborations; Development; Discipline; Drug Delivery Systems; Evaluation; Extramural Activities; Faculty; Faculty Recruitment; Funding; Grant; Human; In Vitro; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Methods; Modeling; Molecular; NCI Center for Cancer Research; Paper; Peer Review; Pharmaceutical Chemistry; Phase; Phase III Clinical Trials; Program Research Project Grants; Publications; Recruitment Activity; Research; Research Personnel; Signal Transduction; Structure; Technology; Therapeutic Agents; Translations; Universities; anti-cancer therapeutic; base; college; comparative; drug discovery; faculty mentor; in vivo; in vivo Model; inter-institutional; meetings; member; novel; oncology; preclinical development; programs; protein protein interaction; screening; structural biology; therapeutic development; tool

Medicinal Chemistry Research Program: Project Summary The Medicinal Chemistry Program (MC) in the Purdue University Center for Cancer Research (PCCR) drives the drug discovery effort of the Center by serving as the central component for basic research in cancer drug discovery and drug discovery methods. The Program consists of 23 members who integrate their expertise in novel synthetic strategies and advanced technologies with the other Research Programs in the Center, to advance translation of promising entities to the clinic. During the past four years, nine new cancer- focused faculty members were recruited to the MC Program. MC members are united by a focus on cancer drug discovery, and represent diverse disciplines that are drawn from seven academic departments and four colleges from across the Purdue campus. The MC Program has a strong publication record, producing 286 papers between 2010 and 2013 with 2% involving intra-programmatic collaborations, 19% representing inter- programmatic and 21% engaging inter-institutional partners; overall, 39% MC publications were a result of collaborative efforts with other cancer researchers. Combined, the MC membership has a current portfolio of over $1.7 million of total direct peer-reviewed, extramural support, with 44% of awards being cancer-focused grants funded by the NCI, NSF, ACS or DOD. The MC Program is structured around two Research Clusters. Research Cluster 1, Synthetic Medicinal Chemistry, and the cornerstone of the MC Program, reflects the strengths of the Center in medicinal chemistry. A distinguished group of senior and junior faculty develops and utilizes target-based medicinal chemistry approaches to drug discovery. The efforts of this group have led to the development of 13 agents that have been in Phase 0, Phase I, Phase II, or Phase III clinical trials in the last funding cycle. Ten other agents have progressed to preclinical development (in vivo studies). Research Cluster 2, Target Discovery and Translation, encompasses a focus on target discovery, in vitro and in cell molecular evaluation of potential anti-cancer therapeutic agents, and the development and use of in vivo models and methods for the analysis of potential anti-cancer drugs. Tools have been developed for high- throughput single cell screening as well as in cell sensing and identifying protein-protein interaction networks. There is a specific emphasis on comparative oncology including studies of dogs with naturally-occurring cancers that closely mimic the human condition. The canine models are being evaluated for their impact on the translation of therapeutic agents to humans. Over the past four years, many MC projects have spawned highly productive inter-programmatic collaborations involving members of the Cell Identity and Signaling (CIS), Chemical and Structural Biology (CSB), and Drug Delivery and Molecular Sensing (DDMS) Programs. The Program Leader and Co-Leader's efforts in cancer-focused faculty recruiting and mentoring, and organizing Program meetings and the PCCR-based Bladder Cancer Discovery Group, have enhanced the two Research Clusters and overall research progress of the MC Program.

药物化学研究计划： 项目摘要 普渡大学癌症研究中心（PCCR）的药物化学项目（MC） 通过作为癌症基础研究的中心组成部分，推动中心的药物发现工作 药物发现和药物发现方法。该计划由23名成员组成，他们将自己的 在新的合成策略和先进技术的专业知识与其他研究计划在 中心，以推进有前途的实体到诊所的翻译。在过去的四年里，九个新的癌症- 专注的教师被招募到MC计划。MC成员因关注癌症而团结在一起 药物发现，并代表来自七个学术部门和四个不同的学科 普渡大学校园里的所有大学MC计划有一个强大的出版记录，生产286 2010年至2013年的论文中，2%涉及项目内合作，19%涉及项目间合作， 方案性出版物和21%的机构间合作伙伴参与;总体而言，39%的MC出版物是 与其他癌症研究人员的合作。MC成员目前的组合包括： 超过170万美元的直接同行评审，校外支持，其中44%的奖项是针对癌症的 由NCI，NSF，ACS或DOD资助的赠款。MC计划围绕两个研究集群结构。 研究集群1，合成药物化学，和MC计划的基石，反映了 中心在药物化学方面的优势。一群杰出的高级和初级教师发展和 利用靶向药物化学方法进行药物发现。这个团体的努力导致了 开发了13种药物，这些药物已在0期、I期、II期或III期临床试验中， 最后一个融资周期。其他10种药物已进入临床前开发阶段（体内研究）。研究 第2组，目标发现和翻译，包括重点目标发现，在体外和细胞 潜在抗癌治疗剂的分子评价，以及体内 用于分析潜在抗癌药物的模型和方法。工具已开发用于高- 单细胞筛选以及细胞传感和识别蛋白质-蛋白质相互作用网络。 有一个特别强调比较肿瘤学，包括狗的研究与自然发生的， 与人类情况极为相似的癌症正在评估犬模型对 将治疗剂转化为人类。在过去的四年里，许多MC项目已经产生了高度 涉及细胞识别和信号传导（CIS）成员的富有成效的跨计划合作， 化学和结构生物学（CSB），药物输送和分子传感（DDMS）程序。的 项目负责人和联合负责人在癌症为重点的教师招聘和指导，并组织 计划会议和基于PCCR的膀胱癌发现小组，加强了两项研究， MC计划的集群和整体研究进展。